Could a pill keep AML at bay? new study tests maintenance therapy after chemo
NCT ID NCT06349239
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looked at whether taking oral azacitidine (Onureg) as maintenance therapy can help older adults with acute myeloid leukemia (AML) stay in remission longer after treatment with CPX-351 chemotherapy. The study included 100 patients aged 65 and older who had achieved remission. Researchers tracked overall survival and side effects to see if this approach is safe and effective for those who cannot undergo a stem cell transplant.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
oral azacitidine (Onureg)
What this could lead to
If successful, this could provide a way to keep AML in remission longer for older patients who cannot have a stem cell transplant.
What could go wrong
This is a small, completed study with no control group, so results may not be definitive. Oral azacitidine can cause side effects like nausea or low blood counts.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHU de Nice
Nice, France